Stock Events

Stock Events

PepGen 

$1.58
0
-$0.04-2.47% Friday 06:52

Statistics

Day High
1.61
Day Low
1.58
52W High
-
52W Low
-
Volume
16,308
Avg. Volume
-
Mkt Cap
108.62M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-0.57
-0.47
-0.37
-0.27
Expected EPS
-0.293333
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-179.96MNet Income

Analyst Ratings

$11.75Average Price Target
The highest estimate is 20.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PEPG.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.44B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases, similar to PepGen's focus on Duchenne muscular dystrophy and myotonic dystrophy.
PTC Therapeutics
PTCT
Mkt Cap5.7B
PTC Therapeutics is involved in the development of genetically targeted therapies for the treatment of rare disorders, competing in the same therapeutic areas as PepGen.
Silence Therapeutics
SLN
Mkt Cap273.96M
Silence Therapeutics develops RNA interference (RNAi) therapies for the treatment of diseases with significant unmet medical need, overlapping with PepGen's RNA platform.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.29B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, directly competing with PepGen's approach to treating genetic disorders.
Ionis Pharmaceuticals
IONS
Mkt Cap12.35B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, making it a direct competitor in the RNA space with PepGen.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other drug development for rare genetic diseases, competing in similar markets as PepGen.
Dyadic International DE
DYAI
Mkt Cap31.52M
Dyadic International, Inc. works on developing and licensing its proprietary C1 gene expression platform for biopharmaceutical drug development, potentially competing in the production of therapies similar to those of PepGen.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.21B
Ultragenyx Pharmaceutical targets rare and ultra-rare diseases with a focus on serious, debilitating genetic diseases, including therapies that could compete with PepGen's products.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is focused on the development of gene-based therapies using CRISPR/Cas9 technology, which could be applied to similar diseases as those targeted by PepGen.
Editas Medicine
EDIT
Mkt Cap261.32M
Editas Medicine works on editing genes to treat a broad range of diseases, including those in PepGen's focus area, making it a competitor in the gene therapy space.

About

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
ISIN
US7133171055

Listings

XNAS
US
PEPG
BOATS
BOATS
PEPG.BOATS

0 Comments

Share your thoughts

FAQ

What is PepGen stock price today?▼
The current price of PEPG.BOATS is $1.58 USD — it has decreased by -2.47% in the past 24 hours. Watch PepGen stock price performance more closely on the chart.
What is PepGen stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange PepGen stocks are traded under the ticker PEPG.BOATS.
What is PepGen market cap?▼
Today PepGen has the market capitalization of 108.62M
When is the next PepGen earnings date?▼
PepGen is going to release the next earnings report on May 07, 2026.
What were PepGen earnings last quarter?▼
PEPG.BOATS earnings for the last quarter are -0.27 USD per share, whereas the estimation was -0.35 USD resulting in a +23.58% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is PepGen revenue for the last year?▼
PepGen revenue for the last year amounts to 0 USD.
What is PepGen net income for the last year?▼
PEPG.BOATS net income for the last year is -179.96M USD.
When did PepGen complete a stock split?▼
PepGen has not had any recent stock splits.